65 related articles for article (PubMed ID: 10859696)
21. Perillyl alcohol: applications in oncology.
Belanger JT
Altern Med Rev; 1998 Dec; 3(6):448-57. PubMed ID: 9855569
[TBL] [Abstract][Full Text] [Related]
22. Where to next with retinoids for cancer therapy?
Smith MA; Anderson B
Clin Cancer Res; 2001 Oct; 7(10):2955-7. PubMed ID: 11595682
[No Abstract] [Full Text] [Related]
23. Tyrosine kinase inhibitors as cancer therapy.
Nichols GL
Cancer Invest; 2003; 21(5):758-71. PubMed ID: 14628434
[No Abstract] [Full Text] [Related]
24. Fasting plus tyrosine kinase inhibitors in cancer.
Caffa I; Longo VD; Nencioni A
Aging (Albany NY); 2015 Dec; 7(12):1026-7. PubMed ID: 26645151
[No Abstract] [Full Text] [Related]
25. Tyrosine kinase inhibitor special issue.
Thamm DH
Vet Comp Oncol; 2012 Sep; 10(3):161-2. PubMed ID: 22882484
[No Abstract] [Full Text] [Related]
26. Retinoids as anticancer agents.
Meyskens FL
J Clin Oncol; 1993 Mar; 11(3):588-9. PubMed ID: 8445437
[No Abstract] [Full Text] [Related]
27. Retinoids: novel immunomodulators and tumour-suppressive agents?
Carratù MR; Marasco C; Mangialardi G; Vacca A
Br J Pharmacol; 2012 Oct; 167(3):483-92. PubMed ID: 22577845
[TBL] [Abstract][Full Text] [Related]
28. Prevention and therapy of tumors with arotinoids.
Sherman MI; Truitt GA
Eur J Cancer Clin Oncol; 1988 Mar; 24(3):359-62. PubMed ID: 3383940
[No Abstract] [Full Text] [Related]
29. Comments to the editor concerning the paper entitled "Preclinical renal cancer chemopreventive efficacy of geraniol by modulation of multiple molecular pathways" Shiekh Tanveer Ahmad et al.
Vuch J; Marcuzzi A; Zanin V; Crovella S
Toxicology; 2012 Mar; 293(1-3):123-124. PubMed ID: 22210290
[No Abstract] [Full Text] [Related]
30. Exploiting liver metabolism for tissue-specific cancer targeting.
Wang Z; Zhu H
Nat Cancer; 2023 Mar; 4(3):310-311. PubMed ID: 36977775
[No Abstract] [Full Text] [Related]
31. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
[TBL] [Abstract][Full Text] [Related]
32. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents.
Morin MJ
Oncogene; 2000 Dec; 19(56):6574-83. PubMed ID: 11426642
[TBL] [Abstract][Full Text] [Related]
33. Synergistic approach to cancer therapy: exploiting interactions between anti-estrogens, retinoids, monoterpenes and tyrosine kinase inhibitors.
Lackey BR; Gray SL; Henricks DM
Med Hypotheses; 2000 May; 54(5):832-6. PubMed ID: 10859696
[TBL] [Abstract][Full Text] [Related]
34. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
Hirokawa Y; Levitzki A; Lessene G; Baell J; Xiao Y; Zhu H; Maruta H
Cancer Lett; 2007 Jan; 245(1-2):242-51. PubMed ID: 16540233
[TBL] [Abstract][Full Text] [Related]
35. Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all?
de Jonge MJ; Verweij J
Eur J Cancer; 2006 Jul; 42(10):1351-6. PubMed ID: 16740386
[TBL] [Abstract][Full Text] [Related]
36. Role of tyrosine kinase inhibitors in cancer therapy.
Arora A; Scholar EM
J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
